The new system developed by Professor Chad Mirkin delivers CRISPR machinery more safely and effectively into cells.

Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.

The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for patent rights to groundbreaking CRISPR gene-editing technology created by ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...